DoW Rare Cancers Resource and Community Development Award
Dept. of Defense — CDMRP · Other Federal · HT942526RCRPRCDA
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $5.6M total
- DeadlineFinal application due date.
- Nov 18, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 5
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Unknown
- Open dateWhen applications open (or opened).
- Jun 17, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $5.6M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Unspecified
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) supports the development of research resources and clinical or preclinical datasets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Research supporting this funding opportunity should fill one of the following major gaps: Lack of research and clinical resources, including patient tissues, cell and tumor models. Lack of communication and dissemination strategies within scientific and patient communities for sharing rare cancers research and clinical findings. Lack of infrastructure for sharing data and other resources. Lack of therapeutics and mechanistic research to inform treatment development. Distinctive Features: Documentation of plans for engagement and partnerships with Patient Advocates throughout the life cycle of the research study from development of the research question through execution of the study. Community building and enhancement are key components. A description of the dissemination and sustainability of the platform for scientific and/or clinical and patient community is required. Preliminary data are not required but may be included to address feasibility.